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Abstract
The effect of folic acid (FA) on breast cancer (BC) risk is uncertain. We hypothesised that this uncertainty may be due, in part, to differential effects of FA
between BC cells with different phenotypes. To test this we investigated the effect of treatment with FA concentrations within the range of unmetabolised
FA reported in humans on the expression of the transcriptome of non-transformed (MCF10A) and cancerous (MCF7 and Hs578T) BC cells. The total
number of transcripts altered was: MCF10A, seventy-ﬁve (seventy up-regulated); MCF7, twenty-four (fourteen up-regulated); and Hs578T, 328 (156 up-
regulated). Only the cancer-associated gene TAGLN was altered by FA in all three cell lines. In MCF10A and Hs578T cells, FA treatment decreased path-
ways associated with apoptosis, cell death and senescence, but increased those associated with cell proliferation. The folate transporters SLC19A1,
SLC46A1 and FOLR1 were differentially expressed between cell lines tested. However, the level of expression was not altered by FA treatment. These
ﬁndings suggest that physiological concentrations of FA can induce cell type-speciﬁc changes in gene regulation in a manner that is consistent with pro-
liferative phenotype. This has implications for understanding the role of FA in BC risk. In addition, these ﬁndings support the suggestion that differences in
gene expression induced by FA may involve differential activities of folate transporters. Together these ﬁndings indicate the need for further studies of the
effect of FA on BC.
Key words: Folic acid: Folate transporters: Cell proliferation: Breast cancer: Microarrays: Folate receptors: Pathway analysis
Folic acid (FA) is the synthetic form of folate that is used in
nutritional supplements and food fortiﬁcation. FA is chemical-
ly more stable and has a higher bioavailability than food
folates(1). It is uncertain whether folate has a beneﬁcial or
adverse effect on the development and progression of breast
cancer (BC)(2–6). However, the relatively few studies that report
the speciﬁc effect of FA on BC risk, as opposed to total intake
of folate, show a consistent negative effect of higher FA
intakes. Women who took FA supplements containing
≥400 µg FA/d showed a 19 % increase in BC risk compared
with those who did not take supplements(7). A case–control
study showed a 53 % increase in BC risk in women who
took FA supplements compared with those who did not(8).
Furthermore, animal models of chemically induced BC have
shown that feeding a diet with a suboptimal FA content sup-
pressed tumorigenesis, possibly by limiting capacity for DNA
synthesis and cell division(9,10). Conversely, FA supplementa-
tion in rats has been shown to enhance the induction, early
promotion, and the progression of mammary tumorigenesis
in some(9,11), but not all(10), studies. Such ﬁndings are of con-
cern because of the high prevalence of multivitamin use in
women with BC or BC survivors(12,13).
Part of the apparent differential effects of FA and folate on
BC may be due to differences in their metabolism. FA and
folates that are absorbed by enterocytes are converted to
5-methyl tetrahydrofolate (5mTHF) which is the main
Abbreviations: 5mTHF, 5-methyl tetrahydrofolate; BC, breast cancer; FA, folic acid.
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chemical form in blood, and which is an important co-factor
in one-carbon metabolism and nucleotide biosynthesis(14).
FA intakes of ≥400 µg/d may result in unmetabolised FA in
blood in addition to higher 5mTHF concentration(15) due to
the lower capacity of enterocytes to convert FA to 5mTHF
compared with folate(16). It is uncertain whether unmetabo-
lised FA induces adverse effects on health(17), although it
has been associated with impaired natural killer cell activity
in women which may have implications for BC risk(18).
Furthermore, since 5mTHF is involved in the supply of
methyl groups to the remethylation cycle in which DNA is a
terminal acceptor, FA may alter BC risk through altered epi-
genetic regulation of tumour suppressor genes as BC can
involve hypermethylation of P16INK4a, BRCA1, BRCA2,
oestrogen receptor (ER)-α, retinoic acid receptor-β2, APC,
and RASSF1A promoters leading to lower transcription and
to impaired DNA repair(19–21).
5mTHF and unmetabolised FA can be assimilated by cells
via either folate receptors, reduced folate carrier protein
(RFCP, SCL19A1) or the proton-coupled folate transporter
(PCFT, SCL46A1)(22). Each of these transporters exhibits a
cell type-speciﬁc distribution and more than one transporter
may be present in each cell type(23–25). Two folate transporters
have been associated with cancer outcomes. Folate receptor-α
(FRα, FOLR1) expression has been shown to be increased in
oestrogen receptor (ER) and progesterone receptor (PR) triple
negative BC cells and is associated with poor prognosis(26),
while RFCP has been shown to be differentially expressed in
B-cell lymphoma(23). Furthermore, the afﬁnity of these folate
transporters for FA is 5- to 10-fold greater than for
5mTHF(27). Thus differences in capacity for FA transport
between BC cell types may be one important factor that deter-
mines the effect of FA on cancer-related processes and so may
contribute to the variation in the outcomes of studies of the
association between folate and FA intakes or status and BC
risk.
To understand better the effect of FA on BC, we investi-
gated the effect of treating non-transformed breast and BC
cell lines with FA concentrations within the range of unmeta-
bolised FA that has been reported previously in blood of
humans taking FA supplements(28) and carried out
transcriptome-wide analysis using microarray. We also investi-
gated whether FA receptor expression differed between these
cell lines.
Methods
Folic acid treatment of cell lines
The three human cell lines used in this study were chosen for
their differences in phenotype. The non-transformed
MCF10A cells acted as a non-tumorigenic control, while
MCF7 and Hs578T cells represented ER-positive and
PR-positive, and triple-negative breast adenocarcinoma
tumours, respectively. MCF10A human non-transformed
breast epithelial cells were obtained from American Type
Culture Collection. Hs578T human cells were obtained from
the European Collection of Cell Cultures. MCF7 human
cells were from our archive, which were derived originally
from cells purchased from the European Collection of Cell
Cultures. All cell lines were cultured at 37°C in an atmosphere
containing 5 % (v/v) CO2, in Dulbecco’s modiﬁed Eagle’s
medium without FA (Sigma), supplemented with 10 % (v/v)
fetal bovine serum (FBS), 2 mM-glutamine, 10 U/ml penicillin
and 100 µg/ml streptomycin. The media for the MCF10A cell
line was further supplemented with 20 ng/ml epidermal
growth factor and 100 µg/ml hydrocortisone. Concentrations
of unmetabolised FA up to 273 nmol/l have been reported
in serum from individuals consuming ≥400 µg FA/d(29).
Cultures were treated with 0 or 100 nmol/l FA for 72 h (n 6
replicates/treatment), the period that allowed maximum cell
yield while maintaining the cultures in a subconﬂuent state.
Background folate concentration derived from FBS in the
medium was 1·5 nmol/l.
Microarray analysis of gene expression
At the end of the treatment period, cells were harvested using
TRI Reagent (Sigma) and total RNA was extracted(30). The
RNA was further puriﬁed using an RNeasy MinElute
Cleanup Kit (Qiagen) according to the manufacturer’s instruc-
tions. RNA concentration and purity were measured using a
Nanodrop ND-1000, and RNA integrity was assessed using
an Agilent 2100 Bioanalyzer (Agilent Technologies). In all
cases the absorbance ratios at 260 and 280 nm were greater
than 2 and RNA integrity number scores were above 7.
Gene expression proﬁles were determined using an Illumina
HumanHT-12 v4 Expression BeadChip microarray (47 231
probes per sample) carried out by Barts and the London
Genome Centre (London, UK), in accordance with the com-
pany’s quality-control procedures using standard protocols for
labelling, hybridisation and washing. The BeadChips were
scanned using an Illumina BeadArray Reader and the data
were quintile normalised in Illumina BeadStudio. A list of dif-
ferentially expressed transcripts was generated using cut-offs
of P value <0·05 and a fold change of at least 1·2 in either dir-
ection. Ingenuity Pathway Analysis (IPA, Qiagen) software was
used to identify functions and molecules that were predicted to
be altered based on the differentially expressed transcripts. All
reported analyses from IPA had z-scores with P< 0·05.
Multiexperiment Viewer (MeV; TM4 Microarray Software
Suite) was used to visualise the signiﬁcantly altered transcripts
from each cell line alongside the corresponding transcripts in
the other cell lines.
Quantitative RT-PCR
Measurement of mRNA expression was carried out essentially
as described previously(31). Brieﬂy, complementary DNA was
prepared from 1 µg of the same RNA as used for the micro-
array using Moloney-murine leukaemia virus reverse tran-
scriptase (Promega). Quantitative RT-PCR was performed in
a total reaction volume of 10 µl with SYBR Green
JumpStart Taq ReadyMix (Sigma) and QuantiTect primer
assays (Table 1; Qiagen). mRNA levels were determined by
the standard curve method(32) and normalised to
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glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expres-
sion, which was found to be unaffected in all three cell lines.
All samples were analysed in duplicate.
Statistical analysis
Statistical analyses were carried out using SPSS (v21; IBM
Corporation). An unpaired Student’s t test was used to analyse
the differences between the control and treated microarray
results. Folate transporter data were analysed by two-way
ANOVA using Bonferroni’s post hoc correction with treatment
and cell line as ﬁxed factors. Differences were considered to be
statistically signiﬁcant at P < 0·05.
Results
Validation of microarray by quantitative RT-PCR
To validate the microarray data, quantitative RT-PCR was per-
formed on four randomly selected transcripts, with varying
magnitudes and directions of change, for each of the three
cell lines. In these three cell lines, 11/12 transcripts measured
by quantitative RT-PCR had the same direction of change in
expression as found with the microarray data (Table 2).
PHF5A in the Hs578T cells showed no change (Table 2).
Folic acid induces differential transcriptome changes in
different breast cancer cell lines
Cut-offs of P value <0·05 and a fold change of at least 1·2 in
either direction were used to generate a list of differentially
expressed transcripts. These data have been deposited in
NCBI’s Gene Expression Omnibus(33) and are accessible
through GEO Series accession number GSE68651 (http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE68651).
The mRNA expression of seventy-ﬁve transcripts differed
signiﬁcantly between the control and treated MCF10A cells
(seventy up-regulated, ﬁve down-regulated). Treatment with
FA in the MCF7 cells induced altered expression in a total
of twenty-four transcripts compared with the control group
(fourteen up-regulated, ten down-regulated). In the Hs578T
cells, FA treatment induced altered expression of 328 tran-
scripts (156 up-regulated, 172 down-regulated). Details of
the differentially expressed transcripts from MCF10A, MCF7
and Hs578T cell lines are reported in Supplementary Tables
S1, S2 and S3, respectively.
The transcripts that were altered signiﬁcantly in each cell line
were visualised using a heatmap against the corresponding
transcripts from the other cell lines (Supplementary Fig. S1).
Comparative analysis showed that the majority of transcripts
with altered expression in response to FA were unique to
each cell line; MCF10A (89 %), MCF7 (75 %) and Hs578T
(97 %) (Fig. 1). FA treatment increased HSPE1 expression
in both MCF10A and MCF7 cells (Table 3). Six transcripts
had altered expression in both MCF10A and Hs578T cells
(Fig. 1). DCN, FTHL3, LOC100130154, LOC128192 and
LOC645979 expression was increased in MCF10A cells, but
decreased expression in Hs578T cells (Table 3). However,
expression of HNRNPC was up-regulated in both MCF10A
and Hs578T cell lines (Table 3). Four transcripts were altered
in both MCF7 and Hs578T cells (Fig. 1(B)). Expression of
RPL8 and C15orf44 was increased in FA-treated MCF7 cells,
Table 2. Validation of microarray analysis by quantitative RT-PCR
(qRT-PCR)
















Fig. 1. Transcripts altered by folic acid (FA) treatment. Comparative analysis
of significantly altered transcripts from each cell line (MCF10a, MCF7 and
Hs578T) after FA treatment. The overlaps between the circles indicate the
transcripts altered in more than one cell line. The identities of these transcripts
and the magnitude of difference are detailed in Table 3.












* Primers were QuantiTect assays purchased from Qiagen. Primer sequences were
not available from the company.
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but decreased in Hs578T cells. Expression of LOC100132394
and LOC100134364 was decreased in FA-treated MCF7 cells,
but increased in Hs578T cells (Table 3). Only one transcript
(TAGLN) was altered by FA treatment in all three cell lines
(Fig. 1). Expression of TAGLN was decreased in MCF10A
and Hs578T cells, but increased in MCF7 cells (Table 3).
Pathway analysis of transcripts altered by folic acid treatment
in MCF10A and Hs578T cells
We were unable to carry out pathway analysis of the effect of
FA treatment on MCF7 cells because of the small number of
transcripts that showed altered expression.
In MCF10A cells, FA treatment increased the predicted acti-
vation scores in ‘migration of cells’, ‘growth of epithelial tis-
sue’, ‘proliferation of tumour cell lines’, ‘vasculogenesis’ and
‘angiogenesis’ pathways. FA treatment decreased the predicted
activation scores for ‘apoptosis’ and ‘cell death’ pathways
(Fig. 2(A)).
In Hs578T cells, FA treatment increased the predicted acti-
vation scores of ‘proliferation of tumour cell lines’, ‘cell sur-
vival’, ‘invasion of cells’ and ‘cell cycle progression of
tumour cell lines’ pathways (Fig. 2(B)). FA treatment decreased
the predicted activation scores of ‘Cell Death’ and ‘Senescence
of Cells’ pathways (Fig. 2(B)).
Upstream regulators are predicted to alter expression in
Hs578T cells
Only the Hs578T data set contained enough altered transcripts
to conduct analysis of upstream regulators. Ten upstream reg-
ulators were predicted based on the changes in gene
Table 3. Transcripts with significantly altered expression in more than one cell line






TAGLN Homo sapiens transgelin (TAGLN), transcript variant 2, mRNA −1·25 1·21 −1·26
HSPE1 Homo sapiens heat shock 10 kDa protein 1 (chaperonin 10) (HSPE1),
mRNA
1·46 1·54 –
DCN Homo sapiens decorin (DCN), transcript variant A1, mRNA 1·29 – −1·26
FTHL3 Homo sapiens ferritin, heavy polypeptide-like 3 (FTHL3), non-coding RNA 1·27 – −1·28
HNRNPC Homo sapiens heterogeneous nuclear ribonucleoprotein C (C1/C2)
(HNRNPC), transcript variant 3, mRNA
1·20 – 1·25
LOC100130154 PREDICTED: Homo sapiens similar to thymosin, β10 (LOC100130154) 1·26 – −1·22
LOC128192 PREDICTED: Homo sapiens hypothetical LOC128192 (LOC128192) 1·34 – −1·30
LOC645979 PREDICTED: Homo sapiens similar to ribosomal protein S26
(LOC645979), mRNA
1·22 – −1·28
RPL8 Homo sapiens ribosomal protein L8 (RPL8), transcript variant 2, mRNA – 1·29 −1·35
C15orf44 Homo sapiens chromosome 15 open reading frame 44 (C15orf44),
transcript variant 2, mRNA
– 1·22 −1·24
LOC100132394 PREDICTED: Homo sapiens hypothetical protein LOC100132394
(LOC100132394), mRNA
– −1·48 2·00
LOC100134364 PREDICTED: Homo sapiens hypothetical protein LOC100134364
(LOC100134364), mRNA
– −1·43 1·72
Fig. 2. Pathway analysis of the effect of folic acid treatment on (A) MCF10A and (B) Hs578T. Pathway analysis was performed using Ingenuity Pathway Analysis
(IPA). Activation z-scores show the predicted activation of each pathway based on the altered transcripts in each cell line. All activation z-scores have P < 0·05.
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expression induced by FA. The activities of FOXM1, FOXO1,
CD24, KIAA1524 and S100A6 were predicted to be
increased, and the activities of NUPR1, TP53, EIF2AK2,
CDKN1A and KDM5B were predicted to be decreased
(Fig. 3). These predicted upstream regulators were identiﬁed
based on the changes in expression of transcripts regulated
by these proteins.
Breast cancer cell lines exhibit differential expression of folate
transporters
The expression of SLC19A1 (RFCP) and SLC46A1 (PCFT),
which are involved in the uptake of unmetabolised FA(22), and
FOLR1 (FRα)(26), which has been linked to BC outcomes,
were measured in MCF10A, MCF7 and Hs578T cell lines.
In both the control and treated cells, expression of each folate
transporter was signiﬁcantly higher in MCF7 cells compared
with both MCF10A and Hs578T cells (Fig. 4). There were
no differences in expression of SLC19A1 or FOLR1 between
the MCF10A and Hs578T cell lines, in either the control or
treated cells (Fig. 4(A), (C)). Expression of SLC46A1 was sig-
niﬁcantly lower in Hs578T cells compared with MCF10A cells
(Fig. 4(B)). However, this effect was lost after FA treatment
(Fig. 4(B)).
Discussion
FA treatment induced cell type-related changes in gene expres-
sion such that the number of transcripts that were expressed
differentially and the proportions of up- and down-regulated
transcripts differed between cell lines. The proportion of tran-
scripts that showed altered expression in only one cell line in
response to FA treatment were MCF10A (89 %), MCF7
(75 %) and Hs578T (97 %). Only the expression of the
cancer-associated gene TAGLN, which encodes transgelin,
was altered by FA in all three cell lines. However, this tran-
script was down-regulated in MCF10A and Hs578T cells,
and up-regulated in MCF7 cells. TAGLN has been shown
previously to be down-regulated in breast, colon and prostate
cancers and in virally transformed cells(34,35), and hence has
been proposed as an early marker of transformation and
tumour progression(34). Conversely, over-expression of
TAGLN has been associated with suppression of cell prolifer-
ation and invasion, and promotion of apoptosis in colorectal
carcinoma(36). Thus the changes in TAGLN expression
induced by FA treatment would be consistent with promotion
of a cancer phenotype in MCF10A and Hs578T cells, but sup-
pression of a cancer phenotype in MCF7 cells. Together these
ﬁndings support the suggestion that the effect of FA on gene
transcription is dependent upon the phenotype of the cells
such that cells of similar histological origin, speciﬁcally adeno-
carcinomas, responded differentially.
Too few genes exhibited altered expression in response to
FA in MCF7 cells to allow pathway analysis. However, both
the non-transformed MCF10A cells and the adenoma-derived
Hs578T cells showed up-regulation of pathways associated
with tumorigenesis including cell migration, cell proliferation
and vascularisation, while pathways associated with apoptosis
and cell differentiation were down-regulated. These ﬁndings
suggest that FA tended to induce changes across the transcrip-
tome that were consistent with the effect on TAGLN and
which would tend to promote a cancer phenotype.
Too few genes in MCF10A or MCF7 cells showed altered
expression in response to FA for analysis of upstream regula-
tors. However, ten upstream regulators were identiﬁed for the
Hs578T cells. FOXM1, FOXO1, CD24, KIAA1524 and
S100A6 were predicted to have increased activity, and
KDM5B, CDKN1A, EIF2AK2, TP53 and NUPR1 were pre-
dicted to have decreased activity. Some of these genes have
functions that relate to BC development and progression
including FOXM(37), FOXO1(38), KIAA1524(39) and
S100A6(40). Furthermore, NUPR1 is a mediator of metastatic
growth that participates in early stages, but not late stages, of
BC development(41). This suggests that these cells develop a
less stable carcinoma phenotype in response to FA.
CDKN1A and TP53 have been shown to function as tumour-
suppressor genes(42,43) and hence FA induced decreased cap-
acity for cell death. Thus consistent with the pathway analysis,
assessment of upstream regulators suggests that FA induced
increased potential for cell proliferation and a more aggressive
cancer phenotype.
It is not possible to deduce from these analyses the precise
mechanism by which FA treatment led to induction of differ-
ential changes in the expression of the transcriptome of these
cell lines. However, one possible mechanism is differences in
the uptake of FA leading to different intracellular FA concen-
trations. It has been reported previously that two folate trans-
porters are associated with cancer outcome(23–25,44,45). The
present ﬁndings show that SLC19A1, SLC46A1 and
FOLR1 are differentially expressed between the three cell
lines investigated. SLC19A1 and FOLR1 expression was
approximately three-fold greater in MCF7 cells compared
with MCF10A or Hs578T cells. SLC46A1 expression was
similar in MCF10A and MCF7cells, which was approximately
two-fold greater than in Hs578T cells. However, the expres-
sion of these folate transporters did not relate in a simple man-
ner to the number of transcripts that showed altered
expression in response to FA. The effect of differential expres-
sion of each folate transporter on FA uptake cannot be
deduced from these data and the effect of any differences in
FA uptake on the BC transcriptome may be modiﬁed by the
capacity of these cell lines to metabolise FA.
The major limitations of the present study are that estab-
lished cell lines were used, which exhibit many differences
other than hormone receptor status that could confound the
results. In order to gain a better understanding of clinical
BC, primary cells derived from tumours of different hormone
status and healthy cells from the same individual would pro-
vide more robust ﬁndings. Although the differences in gene
expression levels were relatively small, the pathway analysis
shows that the ﬁndings are consistent. However, the impact
of differences in gene expression on cell function remains to
be determined. Furthermore, the cell lines were treated with
FA for a relatively short period of time compared with the
exposure of BC cells in women who take dietary supplements
that contain FA. In addition, one previous study has
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shown that BC cell lines undergo phenotypic changes over
time and that such changes are modiﬁed by whether the
cells were grown as a monolayer or a three-dimensional struc-
ture(46). Such effects of duration and type of culture system
may have inﬂuenced the results of the present study.
Nevertheless, the present ﬁndings provide insights into the dif-
ferential effects of FA on BC and proof-of-concept evidence
of possible mechanism of FA action that could form the
basis for studies in more physiological systems.
These ﬁndings provide for the ﬁrst time proof-of-concept
evidence that exposure to FA at a concentration which can
be achieved in humans taking FA dietary supplements(28)
can induce cell type-speciﬁc changes in the transcriptome of
normal and transformed human breast cells. Such effects
may be greater in populations exposed to a diet fortiﬁed
with FA(47,48). Furthermore, these results suggest that there
may be differences in the effect of FA on BC subtypes. If
these ﬁndings were replicated in primary tumour tissue from
women who take FA supplements, then they would have
important implications for dietary recommendations to
women with BC and for the general population. However,
the extent to which generalised recommendations could be
made may be limited by the cell phenotype-speciﬁc nature
of the effects of FA on gene regulation. However, it may be
possible to tailor recommendations to individual patients to
reduce the progress of BC.
Supplementary material
The supplementary material for this article can be found at
http://dx.doi.org/10.1017/jns.2016.8
Fig. 3. Firework plot of predicted upstream regulators in Hs578T cells. Pathway analysis was performed using Ingenuity Pathway Analysis (IPA). Upstream regu-
lators with predicted activation are shown in orange and those with predicted inhibition are shown in blue. Down-regulated transcripts are shown in blue, up-regulated
transcripts are shown in red. The relationships between the altered transcripts and the predicted upstream regulators are indicated by orange lines for activation, blue
lines for inhibition and yellow lines for inconsistent results. Dotted lines indicate theoretical pathway relationships.
Fig. 4. Expression of folate receptors in breast cancer cell lines. The expression of (A) SLC19A1, (B) SLC46A1 and (C) FOLR1 were measured in MCF10A, MCF7
and Hs578T treated with folic acid (100 nmol/l; ■) using quantitative RT-PCR. Values are means, with standard errors represented by vertical bars. Expression levels
were normalised to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and are relative to MCF10A cells treated with 0 nmol/l folic acid (□). Data were analysed
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